You are using an out of date browser that our site does not support. Please, update your browser for a faster browsing experience, better security, and to experience the web's latest features. Click here to update or install a different browser.
Methodist Healthcare Blood and Marrow Transplant Center has been selected to join an elite list of authorized treatment centers in the United States approved to administer the first FDA-approved chimeric antigen receptor T-cell (CAR T) therapy for treatment of patients with acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. Methodist Healthcare Blood and Marrow Transplant Center, located at Methodist University Hospital, is the only treatment center to offer this therapy to patients in the Greater Memphis area, Mississippi and Arkansas.
“We are excited to now offer this novel therapy to patients in Memphis and the surrounding areas who have acute lymphoblastic leukemia and non-Hodgkin’s lymphoma,” said Yasser Khaled, M.D., program director of the Methodist Healthcare Blood and Marrow Transplant Center. “This advanced therapy offers not just hope to patients but possible cures.”
CAR T-cell therapy is a type of immunotherapy called adoptive cell therapy. T-cells – a type of white blood cell – are extracted from the patient’s blood and an artificial receptor called a “chimeric antigen receptor” is added to their surface. The receptor enables the modified cells to produce chemicals that kill cancer. Once infused back into a patient’s body through an IV, they begin multiplying and attacking tumor cells.
For more information on the Methodist Healthcare Blood and Marrow Transplant Center, please visit MethodistHealth.org.